MedTrace Logo

A Study to Determine the Abuse Potential of Seltorexant Compared to Suvorexant and Zolpidem

NCT05106153 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 127

Last updated 2025-04-27

No results posted yet for this study

Summary

The purpose of this study is to evaluate the abuse potential of seltorexant compared to placebo and two active comparators (zolpidem and suvorexant) in non-dependent, recreational sedative users.

Conditions

  • Healthy Non-dependent, Recreational Sedative Users
  • Abuse Potential

Interventions

DRUG

Suvorexant

Suvorexant will be administered orally as per assigned treatment sequence.

DRUG

Zolpidem

Zolpidem will be administered orally as per assigned treatment sequence.

DRUG

Seltorexant

Seltorexant will be administered orally as per assigned treatment sequence.

DRUG

Placebo

Placebo will be administered orally as per assigned treatment sequence.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-12-17
Primary Completion
2023-05-12
Completion
2023-05-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05106153 on ClinicalTrials.gov